Recent Finacing
Recent Raise
Novaremed is a clinical-stage Swiss biopharma developing NRD135S.E1, an orally available non-opioid small molecule for painful diabetic peripheral neuropathy, showing Phase I/IIa efficacy and advancing to Phase IIb.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor
See the team members at Novaremed AG.
